Product Description
Mechanisms of Action: RPE65 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Orphan Drug - Stargardt Disease *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kubota Vision
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Emixustat](https://pryzm-maps.s3.us-west-2.amazonaws.com/332current_maps.png)
Countries in Clinic: Brazil, Canada, Denmark, France, Germany, Italy, Netherlands, South Africa, Spain, United Kingdom, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Macular Degeneration|Stargardt Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SeaSTAR | P3 |
Completed |
Macular Degeneration|Stargardt Disease |
2022-06-13 |